Corcept Investors Face April 21 Deadline to Seek Lead Role in Securities Suit Over Relacorilant

Overview

• In a pending Northern District of California case, investors have until April 21, 2026 to ask to be lead plaintiff in Allegheny County Employees' Retirement System v. Corcept, No. 26-cv-01525.
• The complaint says Corcept told investors relacorilant was close to approval even though the FDA had said the data did not prove effectiveness.
• Filings say the FDA raised these concerns in 2024 and 2025, including issues with the design of Corcept’s pivotal GRACE study.
• After Corcept disclosed an FDA Complete Response Letter, which means no approval as filed, the stock fell about 50%, wiping out nearly $2.5 billion in value.
• The putative class covers purchases from October 31, 2024 through December 30, 2025, and several plaintiff firms are urging CORT investors to seek lead-plaintiff appointment before the deadline.